Effective antibiotics in combination against extreme drug-resistant pseudomonas aeruginosa with decreased susceptibility to polymyxin B

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Lim, Tze Peng ^a,c   Lee, Winnie ^a   Tan, Thean Yen ^b   Sasikala, Suranthran ^a   Teo, Jocelyn ^a   Hsu, Li Yang ^c   Tan, Thuan Tong ^a   Syahidah, Nur ^a   Kwa, Andrea L ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHANGI GENERAL HOSPITAL   (Singapore)

^c Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; LEVOFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; POLYMYXIN B; RIFAMPICIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; OFLOXACIN; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; GENOTYPE; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PHYLOGENY; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PUBLIC HOSPITAL; SINGAPORE; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG POTENTIATION; HUMAN; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; TIME;

AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PHYLOGENY; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RIFAMPIN; THIENAMYCINS; TIME FACTORS;

EID: 82655180452     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028177     Document Type: Article

References (35)

1. Livermore DM, (2007) Introduction: the challenge of multiresistance. Int J Antimicrob Agents 29 (Suppl 3): S1-7.
2. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, et al. (2009) Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 15: 47-53.
3. Navon-Venezia S, Ben-Ami R, Carmeli Y, (2005) Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 18: 306-313.
4. Bonomo RA, Szabo D, (2006) Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43 (Suppl 2): S49-56.
5. Lister PD, Wolter DJ, Hanson ND, (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22: 582-610.
6. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. (2011) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect.
7. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, et al. (2010) Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 54: 1173-1178.
8. Tan TY, Hsu LY, Koh TH, Ng LS, Tee NW, et al. (2008) Antibiotic resistance in gram-negative bacilli: a Singapore perspective. Ann Acad Med Singapore 37: 819-825.
9. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, et al. (2008) Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47: 1298-1304.
10. Giamarellou H, (2010) Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 36 (Suppl 2): S50-54.
11. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, et al. (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13: 560-578.
12. Clinical and Laboratory Standards Institute (2009) Methods for Dilution: Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard- Eighth Edition., vol. 29. Clinical Laboratory Standards Institute,. Wayne, Pennsylvania, USA.
13. Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial testing: Twenty-First Informational Supplement M100-S21. CLSI. Wayne, Pennsylvania, USA.
14. Dawson SL, Fry JC, Dancer BN, (2002) A comparative evaluation of five typing techniques for determining the diversity of fluorescent pseudomonads. J Microbiol Methods 50: 9-22.
15. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, et al. (2005) Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 43: 3129-3135.
16. Ellington MJ, Kistler J, Livermore DM, Woodford N, (2007) Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicrob Chemother 59: 321-322.
17. Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, et al. (1998) Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 42: 849-856.
18. Jaruratanasirikul S, Sriwiriyajan S, Punyo J, (2005) Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 49: 1337-1339.
19. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, et al. (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51: 3781-3788.
20. Kwa AL, Lim TP, Low JG, Hou J, Kurup A, et al. (2008) Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 60: 163-167.
21. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, et al. (2004) Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54: 566-569.
22. Ouderkirk JP, Nord JA, Turett GS, Kislak JW, (2003) Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 47: 2659-2662.
23. Ostronoff M, Ostronoff F, Sucupira A, Souto Maior AP, Caniza M, et al. (2006) Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis 10: 339-340.
24. Pereira GH, Muller PR, Levin AS, (2007) Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 58: 235-240.
25. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, et al. (2007) Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 30: 315-319.
26. Kwa AL, Tam VH, Falagas ME, (2008) Polymyxins: a review of the current status including recent developments. Ann Acad Med Singapore 37: 870-883.
27. Kwa A, Kasiakou SK, Tam VH, Falagas ME, (2007) Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 5: 811-821.
28. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, et al. (2005) Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 49: 4733-4738.
29. Letendre ED, Mantha R, Turgeon PL, (1988) Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis. J Antimicrob Chemother 22: 557-562.
30. Danel F, Hall LM, Gur D, Livermore DM, (1995) OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 39: 1881-1884.
31. Poirel L, Girlich D, Naas T, Nordmann P, (2001) OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother 45: 447-453.
32. Koh TH, Wang GC, Sng LH, (2004) Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore. J Clin Microbiol 42: 5378-5380.
33. TT Tan TK, ML Ling, BH Tan, (2010) Molecular epidemiology and characterization of extensive drug-resistant Pseudomonas aeruginosa outbreak in a hematology unit. 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria.
34. Kunin CM, Craig WA, Kornguth M, Monson R, (1973) Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 226: 214-224.
35. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, et al. (2011) Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula. Antimicrob Agents Chemother 55: 5134-5142.